CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis by Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positi... by Lee, S, Abboud, H, Irani, SR, Nakajima, H, Piquet, AL, Pittock, SJ, Yeh, EA, Wang, J, Rajan, S, Overell, J, Smith, J, St Lambert, J, El-Khairi, M, Gafarova, M, Gelfand, JM